Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine

• DOI: 10.1007/s12253-018-0459-8
• Publication Date: 2018-07-31T05:29:20Z
• Authors: Radosław Mlak; Paweł Krawczyk; Iwona Homa-Mlak; Tomasz Powrózek; Marzanna Ciesielka; Piotr Kozioł; Janusz Milanowski; Teresa Małecka-Ma...
• Keywords: ERCC1; ERCC2

The combination of cisplatin and gemcitabine is still one the most frequently used first-line chemotherapy scheme in patients with advanced non-small cell lung cancer (NSCLC), which tyrosine kinase inhibitors (TKIs) cannot be administered. Unfortunately, more than half have no benefit from but are exposed to its toxic effects. Therefore, single nucleotide polymorphisms (SNPs) genes involved excision repair (NER) mechanism may a potential predictive factor efficiency cytostatic based chemotherapy. aim study was evaluate correlation between SNPs NER effectiveness on NSCLC. group included 91 NSCLC treated using gemcitabine. Genotyping carried out mini-sequencing technique (SNaPshot™ PCR). median progression-free survival (PFS) significantly shorter carriers CC genotype XPD/ERCC2 (2251A > C) gene compared AA/AC genotypes (2 vs. 4.5 months; p = 0.0444; HR 3.19, 95%CI:1.03–9.91). Rare gene, considered as an unfavorable for